Predicting Liver Transplant Capacity Using Discrete Event Simulation by Diaz, Hector Toro et al.
Predicting Liver Transplant Capacity Using Discrete Event 
Simulation
Hector Toro Diaz1, Maria Mayorga2, A. Sidney Barritt 4th3, Eric S. Orman4, and Stephanie B. 
Wheeler5
1Department of Industrial Engineering, Clemson University
2Department of Industrial & Systems Engineering, North Carolina State University
3Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill
4Division of Gastroenterology and Hepatology, Indiana University School of Medicine, 
Indianapolis
5Department of Health Policy and Management, University of North Carolina, Chapel Hill
Abstract
The number of liver transplants (LTs) performed in the US increased until 2006, but has since 
declined despite an ongoing increase in demand. This decline may be due in part to decreased 
donor liver quality and increasing discard of poor quality livers. We constructed a Discrete Event 
Simulation (DES) model informed by current donor characteristics to predict future LT trends 
through the year 2030. The data source for our model is the United Network for Organ Sharing 
database, which contains patient level information on all organ transplants performed in the US. 
Previous analysis showed that liver discard is increasing and that discarded organs are more often 
from donors who are older, obese, have diabetes, and donated after cardiac death. Given that the 
prevalence of these factors is increasing, the DES model quantifies the reduction in the number of 
LTs performed through 2030. In addition, the model estimates the total number of future donors 
needed to maintain the current volume of LTs, and the effect of a hypothetical scenario of 
improved reperfusion technology. We also forecast the number of patients on the waiting list and 
compare this to the estimated number of LTs to illustrate the impact that decreased LTs will have 
on patients needing transplants. By altering assumptions about the future donor pool, this model 
can be used to develop policy interventions to prevent a further decline in this life saving therapy. 
To our knowledge, there are no similar predictive models of future LT use based on epidemiologic 
trends.
Introduction
Liver cirrhosis, which can result in end stage liver disease and hepatocellular carcinoma, is 
the twelfth leading cause of death in the US [1]. The only cure for cirrhosis is liver 
transplantation (LT), which offers patients a 5 year survival rate of 74% [2]. Advances in 
transplantation medicine in the early 1980s transformed LT from an experimental procedure 
to a standard therapy for end stage liver disease [3], and since that time, continued 
improvements in management and outcomes have contributed to an expanding volume of 
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LTs nationally, except in the last decade, where despite an increase in the number of donated 
livers, the number if transplants has slightly declined due to an increase in non use [2].
Despite the increasing number of transplants in the US in the last few decades, demand has 
always exceeded supply. Efforts have been made to increase the donor pool by altering 
procurement strategies to encourage extended criteria donors, including older donors, donors 
with fatty livers, and organ donation after cardiac death (DCD) [4]. In DCD, organs are 
procured after donor circulation ceases, in contrast to standard donation after brain death 
(DBD), where circulation and oxygenation are supported until the time of procurement. The 
problem with these extended criteria donors is that LT outcomes are generally worse for 
recipients of these organs as compared to standard donors (i.e. extended criteria donor livers 
are often considered poor quality organs) [5,6]. Transplant centers are therefore hesitant to 
use livers from donors with advancing age, diabetes, obesity, and DCD, even when the 
donors' other organs (e.g. kidney or pancreas) are successfully transplanted [7, 8].
Patients that require a liver transplant are assigned a Model for End Stage Liver Disease 
(MELD) score based on standard blood work (bilirubin, creatinine and INR), that indicates 
their priority on the waiting list. Wait lists are stratified by ABO blood type. A donor liver is 
offered first to the candidate who matches on common elements, such as blood type and 
body size, and has the highest MELD score (indicating most need). Factors that are 
important for kidney transplants, such as negative lymphocytotoxic crossmatch and the 
number of HLA antigens in common between the donor and the recipient, are a non issue for 
livers. Geographic factors are also taken into consideration; however, while ideally, liver 
grafts are transplanted within 8 hours, they can remain outside the body for 12 to 15 hours, 
and thus, can travel farther than heart and lung grafts. Thus, in current practice, if the 
primary transplant center turns down the donated liver, several other centers will be offered 
the organ; as such, wastage of donated livers is rare. Moreover, since the number of patients 
on the waitlist for livers outnumbers the number of donors, the recipients of donated livers 
are not the limiting factor. Therefore, in this work we focus on the donor liver organs and 
assume that any offered high quality livers would find a donor. However, to show the impact 
of decreased liver utilization, we also forecast the waiting list size and show the gap between 
the waiting list, livers available for transplant, and livers used.
Despite a relatively constant supply of donated livers, the number of transplants performed 
annually in the US has slightly declined since 2006, and decreased donor liver quality may 
be partly responsible. Changing donor characteristics reflecting population wide increases in 
diabetes and obesity along with an emphasis on DCD may have had a deleterious impact on 
the overall number of LTs performed because of increased discard of such organs. 
Knowledge of current donor demographic trends and factors associated with liver discard 
can be used to predict future trends in LT. Such forecasting will aid in developing public 
health policies and programs oriented towards ensuring availability of and access to this life 
saving therapy. To date, forecasting of future liver donor quality and its impact on LT 
volume has not been attempted in the medical literature. Furthermore, forecasting tools 
commonly used in the medical literature, such as Markov and decision tree modeling, are 
imprecise when there are multiple variables that influence outcomes changing over time.
Diaz et al. Page 2
Med Decis Making. Author manuscript; available in PMC 2016 August 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Methods
Data and Overall Approach
The United Network for Organ Sharing (UNOS) database contains extensive patient level 
data on all LTs performed in the US. Data extracted from UNOS and processed through the 
use of different statistical tools were used to inform a discrete event simulation (DES) model 
[9] predicting future LTs. Although we considered using US Census data for demographic 
trends, we found that the UNOS database better represents the population of interest: 
potential organ donors. That is, the UNOS database better represented key health and 
demographic attributes of the organ donor population and these factors (age, race, etc.) and 
the relationships among them were found to be markedly different from other data sources 
including the Census, National Health and Nutrition Examination Survey (NHANES), and 
Behavioral Risk Factor Surveillance System (BRFSS). The model was developed utilizing 
data from 2004 to 2009, with forecasts over the period 2010 2030. Years 2010 and 2011 
were reserved for validation. We began by forecasting demographic trends (age, gender, 
race) accounting for possible correlations. Then we identified factors associated with discard 
of donated livers using multivariable logistic regression analysis. Incorporating the strengths 
of these associations and the changing prevalence of these factors over time, we constructed 
a DES model to estimate future LT utilization. DES enables the tracking of hypothetical 
individuals moving through a model while concurrently considering changing demographic 
and health attributes over time [10].
Inclusion/Exclusion Criteria
In our statistical analysis of the data used to parameterize the DES model, we only include 
donors who had at least one solid organ used for transplant, hence analyzing only those 
donors who met a minimal threshold for organ donation in general (e.g. HIV negative). 
Additionally, only donors at least 18 years of age were included. Living donors and split 
liver donors (where the donated liver is split between two recipients) were excluded because 
these donors make up a very small proportion of donors and their characteristics are very 
different from the general donor population. Another reason to exclude these donors is that 
their liver utilization is 100% as living donations are directed donations to an individual 
(usually a family member) and split donations are organs of high quality usually split 
between two children. Donors with a recorded BMI < 14 or > 50 kg/m2 were also excluded, 
as these extreme values may be reflective of data entry error in the UNOS database. These 
criteria are consistent with our previous work on LT trends [8].
The statistical analysis is restricted to time points between 2004 and 2009 and was inclusive 
of 37, 778 records. While most variables were available since 1995, with varying degrees of 
completeness, we chose to base our model on records from 2004 onward based on our 
interest in recent trends [8] and on the completeness of the data. In particular, alcohol 
consumption was not systematically recorded before this time. However, from 2004 onward, 
each individual variable of interest was missing for <3% of records.
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Statistical Analyses
Independent variables of interest in our logistic regression model included age, obesity (BMI 
≥ 30 kg/m2) diabetes, and DCD. Additional covariates included sex, race and alcohol 
consumption. The primary outcome of interest was a variable indicating whether or not the 
donated liver was used for a transplant. The Likelihood Ratio Test (LRT) [11] was used to 
check whether adding higher order interactions caused significant differences in the 
explanatory power of the logistic regression model. A simpler model was always preferred 
unless it failed the LRT. All statistical processing was done in R (version 2.15.3). Records 
with missing variables were eliminated from the analysis. About 3% of records were 
excluded due to missing variables. Additional details related to the regression models can be 
found in the appendices.
Table 1 presents an overview of the parameters used by the simulation model with additional 
details about the methods by which these variables were generated (i.e., relationships with 
independent variables and statistical models). These model parameters were selected based 
on a retrospective analysis of risk factors for liver discard [8].
Demographic Variables—We analyzed historical demographic trends in the gender, race 
and age of donors in the UNOS database. Our analysis revealed that the proportion of men 
and women in the donor pool has been stable, with the percentage of men being higher, 
accounting for 59% of the donors. Using this information, an empirical discrete probability 
distribution was used to generate the gender of hypothetical individuals moving through the 
simulation model, mirroring historical trends. Our analysis revealed that age, gender and 
race were interrelated; therefore, our analytic and simulation models incorporated 
stratification to appropriately represent this interdependence of important demographic 
variables influencing donation. We have included data from donors reported in UNOS as 
being non Hispanic white, non Hispanic black or Hispanic, with other races (accounting for 
2% of donors) excluded. Race was reported by the local organ procurement organization, 
which is the entity that coordinates the organ donation process. The percentage of donors 
belonging to each race category was generated using linear regression models stratified by 
gender. Following previous work [8], we specified age groups categorically (<30, 30 39, 40 
49, 50 59, and ≥60 years). The probability distribution of age categories is calculated using 
ordinary Least Squares Linear Regression models with stratification by gender and race. 
That is, using the regression, we predict the proportion of simulated individuals in each age 
category, with the age category ≥60 as the referent group; such that the proportion of donors 
in category ≥60 is 1minus the sum of the proportion of donors in all other age categories. 
These proportions then define a discrete distribution from which we draw a donor's age 
category. This is similarly done for race, where Hispanic is used as the referent race 
category. We considered other model specification methods to project gender, race, and age 
(such as moving average and single exponential smoothing); however, linear regression 
models were selected in every case either because the forecasting error was the smallest or 
because, statistically, linear regression yielded predictions equivalent to those from alternate 
models, and the linear regression model was simpler.
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Obesity—The UNOS database contains the BMI of each donor. As a risk factor for liver 
discard, we modeled whether a patient is obese (BMI > 30kg/m2) or not as a dichotomous 
variable. We tested alternate functional forms of BMI, but the use of a continuous variable or 
a more complex categorical variable did not substantially improve the predictive value. 
Because obesity prevalence has increased over time, the likelihood of being obese was 
estimated using a multivariable logistic regression that depends on the demographic 
attributes of the donor as well as on time (Table 1).
Alcohol consumption is reported in the UNOS database as a Yes/No variable (Yes, if ≥ 2 
drinks per day). Although preliminary analysis showed that the overall alcohol consumption 
at the population level has been stable over the time period of analysis, alcohol consumption 
does depend upon demographic attributes, which are changing over time. Accordingly, a 
multivariable logistic regression model was used to predict alcohol consumption based upon 
the demographic attributes of the donor population.
Cause of Death—Livers of donors who die of stroke pose an increased risk for liver graft 
failure after transplant, and are more likely to be discarded compared to other causes of 
death [6, 8]. We originally estimated stroke prevalence as a function of demographic 
attributes, time, diabetes, and obesity. However, in preliminary analyses, stroke prevalence 
was not correlated with diabetes or obesity, so the final logistic regression predicting stroke 
was modeled as a function of demographic attributes and time only. While stroke incidence 
may be correlated to diabetes or obesity in the general population, it is not necessarily the 
case in a successful donor population, which is our population of interest.
Donation after Cardiac Death (DCD) has increased over the last six years as a strategy to 
procure more organs [9]. Thus, the rising trend of DCD was projected by using a linear 
regression model dependent only on time.
Serum bilirubin is a marker of liver dysfunction, and is categorized as ≤ 1.2, 1.3 2.5, 2.6 5.0 
and >5.0 mg/dL, with higher values indicative of worse function. Elevated levels of bilirubin 
among organ donors are typically related to acute illness at the end of life and are not 
generally related to other clinical attributes. Accordingly, the percentage of donors in each 
serum bilirubin category has been stable over time, and these percentages are not related to 
demographic attributes. The serum bilirubin projection was the done by using an empiric 
discrete probability distribution.
Alanine Aminotransferase levels (ALT) are also reflective of liver damage, with mild 
moderate elevations characteristic of stable chronic liver disease (often fatty liver) and more 
severe elevations indicative of acute illness (as with elevated bilirubin). These levels were 
categorized as follows: ≤40, 41 200, 201 400 and >400 U/L. Because the causes of elevated 
ALT differ with respect to the magnitude of the elevation, nested logistic regression models 
were used to forecast ALT. Initially the data were divided into two categories ≤40 and >40, 
and a logistic regression was used to predict the likelihood of being in the ≤40 category. 
Then, among those patients in the category>40, a new logistic regression model was fitted to 
predict the likelihood of being in the 41 200 category. Finally, two subsequent logistic 
regressions were used to predict the likelihood of being in the categories 201 400 and >400. 
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Each of these models was estimated as a function of demographic attributes and time: the 
first model has Age, Obesity, Diabetes and Year as independent variables; the second has 
Age and Year and the third has Age, Diabetes and Year.
Finally, liver nonuse was defined as a liver procured from an organ donor that was not 
transplanted into a recipient. A logistic regression model depending on the remaining 
variables was used to predict whether or not a donated liver would be used for 
transplantation.
Simulation Model
Figure 1 shows how variables are linked in the simulation model. The boxes indicate the 
model variables, directional arrows indicate dependencies between variables, and the gray 
shading indicates that a variable also depends on time (or model year). The model was 
implemented using the software Arena version 15 (Rockwell Automation). We use the 
simulation model to forecast the future availability of livers for transplantation, as well as 
the probability of those livers being utilized. Since the forecast is simulation based, it 
incorporates uncertainties related to key demographic factors as well as health attributes and 
conditions that have been associated with organ donation and organ quality. The simulation 
also takes into account the correlation found among several variables. This is done by 
carefully generating the variables in the order suggested by the flow diagram (Figure 1) so 
that dependencies can be observed and explicitly modeled. The simulation model allows 
individual specific, as opposed to cohort or population based, simulation, which incorporates 
the multiple complex permutations of individual demographic and health attributes with the 
final goal of estimating the number of livers effectively available for and used in 
transplantation over the long term.
The simulation is performed by running 15 replications, each one simulating 100,000 
patients. This number of patients was sufficient to capture the heterogeneity of the donor 
population as well as observe low probability events. This number of replications allowed us 
to achieve a 95% confidence interval half width of 1% or less about our estimate of 
utilization for all years. The confidence intervals describe the reliability of our estimate. The 
accuracy of our results with respect to how well they predict the actual trends is described in 
the Validation Section of the Results.
The Waiting List
To show the impact that the decreased number of LTs would have, it is also important to 
consider the number of patients waiting for a transplant. To forecast the waiting list we use 
data from the Organ Procurement and Transplantation Network (OPTN) (http://
optn.transplant.hrsa.gov). OPTN provides the number on the waiting list at a specific point 
in time, the number of additions to the waiting list, by year, as well as the number of 
removals from the waiting list, by year and cause. We focus on adult (18 years of age and 
over) candidates. We note that candidates are different from registrations. A patient who is 
waiting at more than one center or for multiple organs would be considered a single 
candidate, where as a patient who is waiting at more than one center or for multiple organs 
would have multiple registrations. On January 31, 2014, there were 15, 267 adult patients on 
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the waiting list. We estimate the number of patients prior to 2014 using the following 
equation, number of waiting list candidates in year i+1= number of waiting list candidates in 
year i + number of candidates added in year i number of candidates removed in year i. 
Removal from all causes is considered (deceased or live donor transplant, deceased, 
transplant in another country, etc.). To forecast the waiting list size we use ordinary least 
squares regression with the independent variable year. To be consistent with the simulated 
variables, we use the estimated waitlist size from 2004 to 2009 to fit the model; since we 
were are to query the waitlist at a later date through the OPTN website, we can compare our 
model fit with historical data through 2014.
Study Design (Scenarios)
Several potential scenarios were defined and analyzed. Scenario I assumes that all trends 
projected by the model will continue for the 20 year period. However, some studies have 
suggested that the increase in obesity for adults in the US appears to have stagnated [12]. We 
therefore defined Scenario II in which we suppressed the effect of time after the year 2020 
for all those parameters for which time was a significant predictor, except for the 
demographic parameters. For instance, in the simulation model, obesity and diabetes depend 
on time, but after 2020, the ‘year’ variable was held constant at the 2020 value. Therefore 
predictions of obesity and diabetes in the years after 2020 will depend only on time to the 
extent that demographic trends shift over time.
We then considered an additional plausible scenario that might alter current trends or change 
the risk of liver discard. Scenario III considers an improvement in organ reperfusion 
technology, which could improve the quality of organs previously considered unsuitable for 
transplant [13-16]. Such improvements may mitigate the risk of using fatty livers or DCD 
livers and therefore increase the utility of such livers [13]. Assuming a reperfusion 
technology that becomes available in 2015 and is incorporated into clinical practice with an 
S shaped diffusion of innovation curve [17], and estimating between a 5 to 20% (according 
to a triangular distribution with mode 10%) associated reduction in the risk of liver discard 
for (IIIa) diabetic and obese donors, (IIIb) diabetic or obese donors, and (IIIc) DCD donors, 
we created a new forecast.
In this simulation model, we are required to make assumptions about the expected number 
of donors in the future. Two possibilities are considered. Based on historical data, from 2006 
onward the annual number of adult organ donors meeting our inclusion and exclusion 
criteria has remained relatively constant (around 6,500 donors/year). In the first case, we 
therefore assume that this trend will continue, and this number is held constant. As an 
alternate possibility, we consider an optimistic 3% annual increase in the number of donors 
after 2010.
To show the gap between supply and demand for LTs, we also show our forecast for the 
number of patients on the waiting list. Here again, two possibilities are considered, one in 
which the number of the waiting list continues to increase, and one in which the number of 
candidate on the waiting list remains constant after 2014.
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This study was exempt from review by the University of North Carolina Institutional Review 
Board because it used de identified publically available data (Study # 11 1948).
Results
Validation
Figure 2 illustrates simulated trends for several key variables from years 2004 to 2011, 
overlaid with the historical values for comparison. Recall that years 2010 and 2011 were not 
used in any of the predictive regression models as they were reserved for validation. Overall, 
for each one of the variables being forecasted by the simulation model the estimation error 
was within 1% of the actual historical data. Trends for all variables, simulated and historical, 
are provided in the Appendix. In terms of our forecast of the waiting list, Figure 3 shows 
waiting list candidates from years 2004 to 2014, where the years 2010 through 2014 were 
withheld from the model.
Figure 4 shows the trends in the donor population from 2010 to 2030 for the base scenario 
(Scenario I). Over that 20 year period the proportion of donors over the age of 50 will 
increase from 39% to 44% the prevalence of diabetes among organ donors will increase 
from 14% to 46%, and the prevalence of obesity will increase from 31% to 58%.
Figures 5 and 6 show the results for scenarios I and II respectively under the two 
assumptions for the number of donors in panels (a), the donors remain constant, in panels (b) 
the donors increase by 3% annually. From Figure 5(a) we can see that if the number of 
donors stays at its current level and the trends in all the input parameters continue as before 
(Scenario I), then there will be a continuous decline in the number of LTs. This would be the 
result of a stagnated pool of donors as well as an increasing prevalence of factors associated 
with nonuse, such as older age, obesity, diabetes, and DCD. Figure 5(b) shows that in order 
to maintain the current LT volume, the number of liver donors would need to increase by at 
least 3% per year. However, even with that increase in the number of donors we can see a 
declining trend in LT after 2025. In other words, the deterioration of liver quality will 
eventually surpass the assumed increase in the number of donors.
Figure 6 corresponds to the scenario in which we suppress the effect of time after the year 
2020 in our projections (Scenario II). The same alternative assumptions about the number of 
donors are considered: one case in which the number of donors is held constant at 6,500/
year (panel (a)) and one case in which the number of donors will increase by 3% per year 
(panel (b)). Under the assumption of a constant number of donors, we can see that after 2020 
LTs would continue to decrease, though at a much slower rate, there is only a loss of 58 LTs 
between 2020 and 2030. For the alternative assumption of an increasing number of donors, 
LTs will increase after 2020. Even then, however, the slope of the increase in LT is smaller 
than the slope of the increase in number of donors. In other words, there would still be 
deteriorating quality of donated livers, which will lead to increased discard rates.
In Scenario III we performed a simulation where a hypothetical change in organ reperfusion 
technology was implemented in 2015 over the course of 10 years according to a diffusion 
curve. In the base case, in which the donor pool remained constant, the rate of discard 
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among population of donors who were either obese or diabetic was 60.2% (in 2030). When 
advances in reperfusion affect only donors who are both obese and diabetic (Scenario IIIa), 
this rate of discard is reduced to 57.0%; while if the technique affects either obese or 
diabetic donors (Scenario IIIb), the rate of discard is reduced to 53.1%. The rate of discard 
among DCD donors is reduced from 82.5% to 75.2% if the reperfusion technique is applied 
to DCD livers (Scenario IIIc). Overall, donor utilization was increased by 2.4% to 46.0% by 
2030 when reperfusion techniques were applied to donors with both diabetes and obesity. 
Utilization was increased by 5.2% to 48.8% by 2030 if the technology benefitted patients 
with either diabetes or obesity. Utilization increased by 3.5% to 47.1% by 2030 when new 
reperfusion technology reduced the risk of DCD liver discard. The results are shown in 
Figure 7, for the base case, in which the donor pool remains constant, all three versions of 
the technology effect are shown with our original predictions also shown as “no change”.
Lastly, we forecast the waitlist size, and again consider two cases. In one case (panel (a)), 
the wait list size stays constant after 2014, in the other case (panel (b)) it continues to 
increase as per our forecast. Figure 8 shows the gap between supply and demand (wait list 
minus LTs) assuming the donor pool remains constant for scenarios I, II, and III (c).
Discussion
A decreasing trend in the number of livers being transplanted has been observed previously 
[8]. Given the importance of LT as an option to save lives, this decreasing trend generates 
concerns about the ability of current liver donation processes to meet future demand. In this 
context, we modeled the current system and forecasted future supply and non use of livers to 
better inform decision making about policies that may be implemented to improve donation 
outcomes and reduce waitlist size. Several variables affect the final decision of using or 
discarding a donated liver, including: demographic attributes, clinical risk factors, 
epidemiologic factors and comorbidities. To identify which factors are most relevant to the 
decline in liver use, and which are most modifiable, we develop a DES model that captures 
these complexities by allowing for interrelationships among variables to exist over time.
Our analyses indicate that observed trends in donor characteristics are expected to result in 
further declines in LTs in 5, 10, and 20 years. One strength of our approach is that DES 
modeling allows us to estimate these changes with precision. Furthermore, the DES model 
allows us to estimate how many additional donors will need to be recruited to maintain 
current LT levels. Our forecast of the waiting list size allows us to estimate the gap between 
supply and demand for livers. Such information can be critical to helping design policies to 
sustain or augment the number and quality of livers available for transplant. DES also allows 
for creating and evaluating “what if” scenarios. Since we are including the modeling of each 
input parameter as a separate module, it is possible to evaluate the effect of possible changes 
on a particular variable (or several of them, probably interrelated), as a result of changes in 
policies, procedures or technologies, for instance. This can be useful to inform policy 
makers about alternative ways to improve the utilization of donated livers. One such 
example was provided in Scenario III, where we considered the hypothetical scenario of 
improved reperfusion technology. Results show that such improvements, as optimistic as 
they are, can only reduce the rate of discard by about 5%. Thus, the total utilization rate will 
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still remain lower than current levels despite these optimistic assumptions. This model can 
be used in future studies to help influence donation and procurement policies in the context 
of increasing rates of metabolic disease and consequent liver discard. That is, it can help us 
to quantify the effectiveness of policy changes with respect to existing procurement 
strategies, such as extended criteria donation. Regarding future trends in the underlying 
donor population, the current model makes assumptions about the expected number of 
donors available in the future and the composition of the donor population. While we 
consider changes in the aggregate number (constant versus an annual 3% increase, obesity 
increases versus stagnates) the current model does not incorporate a detailed forecast of the 
entire donor pool, i.e. those patients/families that decline organ donation. One way to 
incorporate a detailed model of the supply of liver donations would be to use the census 
population and mortality rates for different demographics (such as age and race) jointly with 
a model for either likelihood of donation, based on historical rates of donation by strata, or a 
model for “willingness to donate” which considers that drivers of donation (such as patient 
demographics, religious beliefs and state level opt in policies) may change over time. 
However, we suspect that this forecast for liver graft availability may be rendered even more 
pessimistic if demographic shifts in the U.S. trend toward populations that have historically 
low organ donation rates [18]. While it is outside the scope of this research, as future work, 
we would like to expand the model so that it can also be used to quantify changes in policies 
that improve organ donation.
DES is a strong methodological approach over other commonly used models, such as 
Markov processes. By using DES we were able to employ different statistical processing 
tools for each relevant input parameter, selecting in each case the statistical tool that better 
suited the forecast of each variable. DES models have been used in the past in relation to 
liver transplantation. In [19] the authors developed a DES framework to model the US liver 
allocation system incorporating the stochastic disease specific natural history of patients. 
They mentioned that their model could be used for estimating the number of transplants 
performed as well as the number of wasted livers, among other statistics of interest. In [10] 
the authors also used DES to build a biologically based model of liver transplantation so that 
changes in allocation policies could be evaluated. The work in [20] describes a family of 
simulations developed by the US Scientific Registry of Transplant Recipients, used to 
predict the likely effects of different allocation policies. In [21] they used a multistage 
Markov decision analysis model to analyze the survival chances under different treatments 
of patients requiring liver transplantation. The authors mention that although many problems 
can be modeled by Markov Decision Process (MDP), when the number of states is too large 
or the system is complex enough so that MDP's parameters become hard to estimate, 
simulation becomes a valid alternative with high precision and reasonable computation time. 
We are using DES, taking advantage of its ability to deal with a system in which there are 
complex relationships among key variables. Furthermore, unlike the works mentioned we 
are not modeling the allocation policies. Instead we are interested in predicting the 
availability of livers and their quality. The allocation process is a step further once a suitable 
liver becomes available. We have not found previous research attempting to analyze the 
future availability of livers for transplantation, taking into account the explanatory factors of 
the quality of the livers being donated.
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A number of limitations accompany our analyses. For example, not all available variables 
were included in the analysis (e.g. self reported drug use); adding these variables could 
enhance the predictive power of the model; however there are concerns about reliability of 
variables such as drug use due to inherent bias in self report. In addition, some of the 
variables that we used were categorized to facilitate the analysis, which has been a common 
practice in previous research. However it may be the case that keeping all the information 
from the variables can improve the accuracy of the forecast. As with any forecast, this is an 
extrapolation into the future, which is unknown. While we have shown that the model 
adequately predicted the years 2010 and 2011, its accuracy beyond that is unknown. Major 
shifts in demographic and clinical factors in the population, as well as major shifts in 
technology could impact utilization. We have tried to take this into account to the extent 
possible by considering hypothetical scenarios, such as changes in obesity trends and 
changes in organ reperfusion technology. Lastly, as previously discussed, the current model 
does not include a detailed forecast of those patients/families that decline organ donation.
In conclusion, this work is the first to forecast liver's availability and quality at the US 
population level with high level of accuracy. Results show that if current trends continue this 
could result in 2230 (44%) fewer LTs by 2030. In order to maintain the number of LTs from 
2010, despite these trends, 5115 additional organ donors will be needed in 2030. 
Furthermore, if waitlist size continues to grow at the same rate, there will be 12429 
candidates on the list in 2030 who do not receive a liver. This grim outcome cannot be 
mitigated alone by even radical technological advances, a stabilization of negative clinical 
attributes (such as obesity) or an increase in the donor population. Likely, a combination of 
strategies that increase donor pool, improve donor liver quality, and make better use of 
inferior quality livers, will be necessary to keep up with LT demand. Unless the transplant 
community develops improved strategies for organ allocation and utilization, the only way to 
maintain the number of LTs at the current levels may be to accept inferior grafts at the risk 
worse post transplant outcomes.
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Appendix
Simulation Model Implementation Details
Below are the distributions used in the model for each independent variable.
Gender
Discrete distribution, 41.3% female, 58.7% male
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Age
Age category is assigned according to a discrete distribution that changes over time and 
depends on gender. The probability that age category x is assigned in year is given by 
P(x,y)= α(x)+βy for x={<30, 30-39, 40-49, 50-59}. P(60, y)= 1-Σx<60 P(x,y). In these 
equations “α”s are given by the “Intercept” estimates and “β”s are given by the “Year” 
estimates shown in the Regression Details Section of the Appendix.
Race
Race category is assigned according to a Discrete distribution that changes over time and 
depends on gender. The probability that Race category x is assigned in year is given by 
P(x,y)= α(x)+βy for x={White, Black}. P(Hispanic, y)= 1-Σx<60 P(x,y). In these equations 
“α”s are given by the “Intercept” estimates and “β”s are given by the “Year” estimates 
shown in the Regression Details Section of the Appendix.
The variables BMI, Alcohol, Diabetes, Stroke, and Use are modeled using logistic 
regressions. Where we obtain P(Y) using P(Y)= e^(Y)/[1+e^Y]; Y= β0+-Σj βj. β0 
corresponds to intercept estimates and βjs correspond to the estimates for each of the 
dependent variables listed in the Regression Details Section of the Appendix. Then P(Y) is 
used to sample from a discrete distribution with a binary outcome, yes or no.
Bilirubin
Discrete distribution categorized as ≤ 1.2, 1.3-2.5, 2.6 -5.0 and >5.0 mg/dL with the 
respective probabilities: 73.7%, 21.0%, and 4.0% and 1.3%
DCD
Assigned according to a discrete distribution that changes over time. The probability the 
organ comes from a DCD donor in year is given by P(y)= α+βy where “α” is given by the 
“Intercept” estimate and “β” is given by the “Year” estimate shown in the Regression Details 
Section of the Appendix.
ALT
First, we divide the data into two categories, ≤40 and >40, and a logistic regression was used 
to predict the likelihood of being in the ≤40 category. Then, among those patients in the 
category>40, a new logistic regression model was fitted to predict the likelihood of being in 
the 41-200 category. Finally, two subsequent logistic regressions were used to predict the 
likelihood of being in the categories 201-400 and >400. The probabililities of being in each 
of the binary categories at each step is calculated as explained for the other variables using 
logistic regression above. Then, we use conditional probabilities to obtain the probabilities 
of being in each of the original 4 categories. That is Pr(≤40) is given right away, as the first 
regression provides Pr(≤40) and Pr(>40)=1- Pr(≤40). Then Pr(41-200)= Pr(41-200|
>40)xPr(>40). This is repeated for the other categories.
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Waitlist
Waitlist size Y follows a linear regression where Y=α+βy. In this case y is the current year, 
such as 2004.
Regression Models Details
Male - Age <30
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 0.307051 0.007361 41.714 3.03e-05
Year -0.004563 0.003005 -1.519 0.226
Residual standard error: 0.009503
Multiple R-squared: 0.4346, Adjusted R-squared: 0.2461, p-value: 0.2262
Male - Age 30-39
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 1.521e-01 2.559e-03 59.438 1.05e-05
Year 4.096e-05 1.045e-03 0.039 0.971
Residual standard error: 0.003303
Multiple R-squared: 0.0005123, Adjusted R-squared: -0.3327, p-value: 0.9712
Male - Age 40-49
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 0.2126201 0.0047586 44.68 2.47e-05
Year -0.0007567 0.0019427 -0.39 0.723
Residual standard error: 0.006143
Multiple R-squared: 0.04814, Adjusted R-squared: -0.2691, p-value: 0.7229
Male - Age 50-59
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 0.194718 0.004380 44.457 2.51e-05
Year 0.004403 0.001788 2.462 0.0907
Residual standard error: 0.005654
Multiple R-squared: 0.6689, Adjusted R-squared: 0.5586, p-value: 0.0907
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Male - Age >60
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 0.1335192 0.0048541 27.506 0.000105
Year 0.0008765 0.0019817 0.442 0.688207
Residual standard error: 0.006267
Multiple R-squared: 0.06122, Adjusted R-squared: -0.2517, p-value: 0.6882
Female - Age <30
Coefficients:
Estimate Std. Error t value Pr(> |t|)
(Intercept) 0.158056 0.005804 27.233 0.000109
Year 0.002390 0.002369 1.009 0.387421
Residual standard error: 0.007493
Multiple R-squared: 0.2533, Adjusted R-squared: 0.00435, p-value: 0.3874
Female - Age 30-39
Coefficients:
Estimate Std. Error t value Pr(> |t|)
(Intercept) 0.134720 0.008739 15.417 0.000593
Year -0.000486 0.003567 -0.136 0.900268
Residual standard error: 0.01128
Multiple R-squared: 0.006148, Adjusted R-squared: -0.3251, p-value: 0.9003
Female - Age 40-49
Coefficients:
Estimate Std. Error t value Pr(> |t|)
(Intercept) 0.248626 0.007147 34.788 5.22e-05
Year 0.000337 0.002918 0.116 0.915
Residual standard error: 0.009227
Multiple R-squared: 0.004427, Adjusted R-squared: -0.3274, p-value: 0.9153
Female - Age 50-59
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 0.246048 0.005810 42.347 2.9e-05
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Year 0.003255 0.002372 1.372 0.264
Residual standard error: 0.007501
Multiple R-squared: 0.3856, Adjusted R-squared: 0.1808, p-value: 0.2636
Female - Age >60
Coefficients:
Estimate Std. Error t value Pr(> 111)
(Intercept) 0.212550 0.006124 34.706 5.26e-05
Year -0.005494 0.002500 -2.197 0.115
Residual standard error: 0.007906
Multiple R-squared: 0.6168, Adjusted R-squared: 0.4891, p-value: 0.1155
Male - Race White
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 0.747167 0.007111 105.071 7.52e-14
Year -0.008250 0.001332 -6.194 0.000261
Residual standard error: 0.0121
Multiple R-squared: 0.8275, Adjusted R-squared: 0.8059, p-value: 0.0002612
Male - Race Black
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 0.1222422 0.0026032 46.959 4.68e-ll
Year 0.0042008 0.0004876 8.615 2.55e-05
Residual standard error: 0.004429
Multiple R-squared: 0.9027, Adjusted R-squared: 0.8905, p-value: 2.553e-05
Male - Race Hispanic
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 0.130590 0.005766 22.65 1.53e-08
Year 0.004050 0.001080 3.75 0.00563
Residual standard error: 0.00981
Multiple R-squared: 0.6374, Adjusted R-squared: 0.592, p-value: 0.005625
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Female - Race White
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 0.799906 0.005799 137.946 8.53e-15
Year -0.009455 0.001086 -8.705 2.37e-05
Residual standard error: 0.009866
Multiple R-squared: 0.9045, Adjusted R-squared: 0.8926, p-value: 2.367e-05
Female - Race Black
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 0.102636 0.005867 17.493 1.16e-07
Year 0.007446 0.001099 6.775 0.000141
Residual standard error: 0.009982
Multiple R-squared: 0.8516, Adjusted R-squared: 0.833, p-value: 0.0001414
Female - Race Hispanic
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) 0.0974578 0.0040719 23.934 9.89e-09
Year 0.0020092 0.0007627 2.634 0.03
Residual standard error: 0.006928
Multiple R-squared: 0.4645, Adjusted R-squared: 0.3975, p-value: 0.02999
BMI
Coefficients:
Estimate Std. Error z value Pr(> | z |)
(Intercept) -87.366924 19.148313 -4.563 5.05e-06
GenderM -1.109458 0.126132 -8.796 < 2e-16
Age>=60 0.237314 0.136855 1.734 0.082909
Age30-39 0.270857 0.140752 1.924 0.054310
Age40-49 0.341998 0.122704 2.787 0.005317
Age50-59 0.422617 0.124174 3.403 0.000665
RaceHispanic 2.439582 27.969924 0.087 0.930495
RaceWhite -51.064656 20.915100 -2.442 0.014626
year 0.043198 0.009547 4.525 6.05e-06
GenderM :Age>=60 0.331250 0.188505 1.757 0.078875
GenderM :Age30-39 0.687985 0.179629 3.830 0.000128
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GenderM :Age40-49 0.498453 0.160411 3.107 0.001888
GenderM:Age50-59 0.170108 0.165596 1.027 0.304305
GenderM:RaceHispanic 0.721618 0.179217 4.026 5.66e-05
GenderM:RaceWhite 0.691696 0.140777 4.913 8.95e-07
Age>=60:RaceHispanic 0.242861 0.208022 1.167 0.243017
Age30-39:RaceHispanic 0.443973 0.205978 2.155 0.031127
Age40-49:RaceHispanic 0.346030 0.186828 1.852 0.064007
Age50-59:RaceHispanic 0.439398 0.188255 2.334 0.019593
Age>=60:RaceWhite 0.164633 0.150857 1.091 0.275133
Age30-39: RaceWhite 0.264082 0.156605 1.686 0.091740
Age40-49: RaceWhite 0.235071 0.136988 1.716 0.086162
Age50-59: RaceWhite 0.252462 0.138082 1.828 0.067499
RaceHispanicyear -0.001532 0.013947 -0.110 0.912520
RaceWhite:year 0.025103 0.010429 2.407 0.016079
GenderM:Age>=60:RaceHispanic -0.524963 0.281716 -1.863 0.062399
GenderM:Age30-39:RaceHispanic -0.861232 0.255950 -3.365 0.000766
GenderM:Age40-49:RaceHispanic -0.429464 0.235367 -1.825 0.068053
GenderM:Age50-59:RaceHispanic -0.200124 0.241284 -0.829 0.406872
GenderM:Age>=60:RaceWhite 0.149804 0.206032 0.727 0.467171
GenderM:Age30-39:RaceWhite -0.519040 0.200004 -2.595 0.009455
GenderM:Age40-49:RaceWhite -0.155751 0.178376 -0.873 0.382576
GenderM:Age50-59:RaceWhite 0.217655 0.182938 1.190 0.234133
Null deviance: 2110.55 on 299 degrees of freedom
Residual deviance: 284.23 on 267 degrees of freedom
AIC: 1825.1
Alcohol
Coefficients:
Estimate Std. Error z value Pr(> | z |)
(Intercept) -3.46135 0.16378 -21.134 < 2e-16
GenderM 0.93232 0.13353 6.982 2.91e-12
Age>=60 0.72548 0.19842 3.656 0.000256
Age30-39 1.26358 0.18671 6.768 1.31e-ll
Age40-49 1.68070 0.16647 10.096 < 2e-16
Age50-59 1.37501 0.16928 8.123 4.56e-16
RaceHispa -0.08106 0.19433 -0.417 0.676593
RaceWhite 0.81997 0.14770 5.551 2.83e-08
GenderM :Age>=60 0.18205 0.13324 1.366 0.171843
GenderM :Age30-39 -0.03443 0.12959 -0.266 0.790461
GenderM :Age40-49 -0.07111 0.11535 -0.616 0.537600
GenderM:Age50-59 0.15922 0.11763 1.354 0.175880
GenderM:RaceHispa 0.47804 0.14217 3.362 0.000773
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GenderM:RaceWhite -0.05577 0.09621 -0.580 0.562159
Age>=60:RaceHispa -0.17169 0.23113 -0.743 0.457584
Age30-39:RaceHispa -0.18022 0.19864 -0.907 0.364254
Age40-49: RaceHispa -0.28060 0.18167 -1.545 0.122458
Age50-59:RaceHispa -0.25913 0.18676 -1.387 0.165294
Age>=60:RaceWhite -0.54777 0.17752 -3.086 0.002030
Age30-39: RaceWhite -0.40926 0.16368 -2.500 0.012406
Age40-49: RaceWhite -0.50664 0.14544 -3.484 0.000495
Age50-59: RaceWhite -0.52747 0.14739 -3.579 0.000345
Null deviance: 1996.1471 on 29 degrees of freedom
Residual deviance: 2.0629 on 8 degrees of freedom
AIC: 234.8
Diabetes
Coefficients:
Estimate Std. Error z value Pr(>|z|)
(Intercept) -1.888e+02 1.796e+01 -10.509 < 2e-16
GenderM -1.021e+00 1.326e-01 -7.695 1.41e-14
RaceHispa 4.220e+01 2.644e+01 1.596 0.110435
RaceWhite 4.398e+01 1.971e+01 2.232 0.025625
Age>=60 2.204e+00 1.816e-01 12.137 < 2e-16
Age30-39 8.240e-01 2.040e-01 4.039 5.38e-05
Age40-49 1.336e+00 1.811e-01 7.378 1.61e-13
Age50-59 1.817e+00 1.783e-01 10.189 < 2e-16
Year 9.237e-02 8.960e-03 10.309 < 2e-16
ObeseY 7.966e-01 2.898e-02 27.489 < 2e-16
GenderM: RaceHispa -3.656e-02 9.998e-02 -0.366 0.714580
GenderM: RaceWhite 1.731e-01 7.530e-02 2.299 0.021487
GenderM:Age>=60 1.374e+00 1.276e-01 10.769 < 2e-16
GenderM:Age30-39 6.743e-01 1.482e-01 4.549 5.38e-06
GenderM :Age40-49 1.028e+00 1.302e-01 7.897 2.85e-15
GenderM:Age50-59 1.129e+00 1.264e-01 8.935 < 2e-16
RaceHispa:Age>=60 -4.825e-02 2.361e-01 -0.204 0.838083
RaceWhite:Age>=60 -8.108e-01 1.847e-01 -4.391 1.13e-05
RaceHispa:Age30-39 -1.528e-01 2.648e-01 -0.577 0.563940
RaceWhite:Age30-39 -4.415e-01 2.086e-01 -2.117 0.034280
RaceHispa:Age40-49 1.441e-01 2.340e-01 0.616 0.538220
RaceWhite:Age40-49 -6.581e-01 1.849e-01 -3.559 0.000372
RaceHispa:Age50-59 5.486e-02 2.310e-01 0.237 0.812287
RaceWhite:Age50-59 -6.323e-01 1.816e-01 -3.482 0.000498
RaceHispa:Year -2.105e-02 1.319e-02 -1.596 0.110554
RaceWhite:Year -2.196e-02 9.831e-03 -2.234 0.025498
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Null deviance: 42409 on 76898 degrees of freedom
Residual deviance: 37177 on 76873 degrees of freedom
AIC: 37229
DCD
Coefficients:
Estimate Std. Error t value Pr(>|t|)
(Intercept) -0.0051997 0.0072109 -0.721 0.503
Year 0.0118093 0.0009905 11.923 7.32e-05
Residual standard error: 0.005241
Multiple R-squared: 0.966, Adjusted R-squared: 0.9592, p-value: 7.315e-05
Stroke
Coefficients:
Estimate Std. Error z value Pr(>|z|)
(Intercept) -8.862e-01 1.569e+01 -0.056 0.954965
Age>=60 4.484e+01 1.527e+01 2.938 0.003308
Age30-39 2.764e+01 1.380e+01 2.003 0.045227
Age40-49 6.030e+01 1.296e+01 4.653 3.28e-06
Age50-59 8.523e+01 1.362e+01 6.258 3.89e-10
GenderM -3.422e+01 7.978e+00 -4.289 1.80e-05
RaceHispa -4.683e-01 1.676e+01 -0.028 0.977709
RaceWhite 7.619e+01 1.260e+01 6.048 1.47e-09
Year -1.507e-04 7.834e-03 -0.019 0.984652
Age>=60:GenderM 6.099e-01 6.695e-02 9.109 < 2e-16
Age30-39:GenderM 1.765e-01 6.297e-02 2.803 0.005070
Age40-49:GenderM 3.685e-01 5.863e-02 6.286 3.26e-10
Age50-59:GenderM 4.979e-01 6.099e-02 8.164 3.23e-16
Age>=60:RaceHispa -5.845e-01 1.355e-01 -4.314 1.60e-05
Age30-39:RaceHispa -3.238e-01 1.104e-01 -2.932 0.003363
Age40-49: RaceHispa -5.035e-01 1.055e-01 -4.773 1.81e-06
Age50-59:RaceHispa -5.203e-01 1.142e-01 -4.556 5.21e-06
Age>=60:RaceWhite -9.037e-02 1.068e-01 -0.846 0.397635
Age30-39: RaceWhite -2.354e-01 8.965e-02 -2.626 0.008650
Age40-49: RaceWhite -4.786e-01 8.435e-02 -5.674 1.40e-08
Age50-59: RaceWhite -3.388e-01 9.072e-02 -3.734 0.000188
Age>=60:Year -2.081e-02 7.619e-03 -2.732 0.006302
Age30-39:Year -1.303e-02 6.891e-03 -1.891 0.058670
Age40-49:Year -2.882e-02 6.470e-03 -4.455 8.41e-06
Age50-59:Year -4.106e-02 6.797e-03 -6.041 1.53e-09
GenderM:RaceHispa 2.268e-02 7.255e-02 0.313 0.754560
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GenderM: RaceWhite 1.110e-01 5.502e-02 2.017 0.043668
GenderM :Year 1.645e-02 3.983e-03 4.130 3.63e-05
RaceHispa:Year 2.923e-04 8.368e-03 0.035 0.972135
RaceWhite:Year -3.824e-02 6.289e-03 -6.081 1.20e-09
Null deviance: 27343.4 on 1722 degrees of freedom
Residual deviance: 2167.2 on 1693 degrees of freedom
AIC: 6752.4
ALT - <=40 - >40
Coefficients:
Estimate Std. Error z value Pr(> | z |)
(Intercept) 66.060988 3.480759 18.979 < 2e-16
AgeCat>=60 0.985003 0.026545 37.107 < 2e-16
AgeCat30-39 0.090342 0.023593 3.829 0.000129
AgeCat40-49 0.274738 0.021614 12.711 < 2e-16
AgeCat50-59 0.509089 0.022732 22.396 < 2e-16
Obese.Y -0.265279 0.018350 -14.457 < 2e-16
Diabetes.Y 0.132932 0.029767 4.466 7.98e-06
year -0.032894 0.001738 -18.923 < 2e-16
Null deviance: 2627.2 on 318 degrees of freedom
Residual deviance: 327.8 on 311 degrees of freedom
AIC: 1858.5
ALT - 41-200 - >200
Coefficients:
Estimate Std. Error z value Pr(>|z|)
(Intercept) 70.407817 7.656245 9.196 < 2e-16
AgeCat>=60 0.981491 0.072491 13.539 < 2e-16
AgeCat30-39 0.149785 0.045355 3.302 0.000958
AgeCat40-49 0.397113 0.043958 9.034 < 2e-16
AgeCat50-59 0.669555 0.050792 13.182 < 2e-16
year -0.034443 0.003822 -9.012 < 2e-16
Null deviance: 740.80 on 314 degrees of freedom
Residual deviance: 332.18 on 309 degrees of freedom
AIC: 1300.8
ALT - 201-400 - >400
Coefficients:
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Estimate Std. Error z value Pr(>|z|)
(Intercept) 51.58996 14.12514 3.652 0.000260
AgeCat>=60 0.69847 0.14491 4.820 1.44e-06
AgeCat30-39 0.13017 0.08229 1.582 0.113692
AgeCat40-49 0.21430 0.08094 2.648 0.008107
AgeCat50-59 0.35092 0.09622 3.647 0.000265
Diabetes.Y 0.26195 0.13305 1.969 0.048972
year -0.02581 0.00705 -3.661 0.000252
Null deviance: 346.95 on 265 degrees of freedom
Residual deviance: 293.42 on 259 degrees of freedom
AIC: 869.3
Liver Usage
Coefficients:
Estimate Std. Error z value Pr(>|z|)
(Intercept) 103.34785 20.16547 5.125 2.98e-07
Age>=60 -0.84203 0.06327 -13.309 < 2e-16
Age30-39 -0.44170 0.05990 -7.373 1.66e-13
Age40-49 -0.90414 0.05386 -16.788 < 2e-16
Age50-59 -1.05926 0.05551 -19.082 < 2e-16
GenderM 0.12925 0.03422 3.777 0.000159
RaceHispa -0.84163 0.06341 -13.272 < 2e-16
RaceWhite -0.41177 0.05291 -7.783 7.08e-15
AlcohY -0.87527 0.03822 -22.904 < 2e-16
ObeseY -0.67870 0.03445 -19.701 < 2e-16
DiabetesY -0.13673 0.05070 -2.697 0.007000
StrokeY -0.18463 0.03734 -4.944 7.65e-07
DCD1: Yes -2.25521 0.04688 -48.111 < 2e-16
Altcat1: 41-200 -0.51481 0.03494 -14.736 < 2e-16
Altcat2: 201-400 -1.00249 0.08017 -12.504 < 2e-16
Altcat3: >400 -2.25609 0.07138 -31.605 < 2e-16
Bilicat1: 1.2-2.5 -0.43682 0.03939 -11.090 < 2e-16
Bilicat2: 2.5-5 -1.08503 0.06776 -16.012 < 2e-16
Bilicat3: >5 -2.25948 0.12118 -18.646 < 2e-16
year -0.04953 0.01005 -4.930 8.24e-07
Null deviance: 15548 on 8516 degrees of freedom
Residual deviance: 9696 on 8497 degrees of freedom
AIC: 13797
Waitlist Size
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Coefficients Standard Error t Stat P-value
Intercept -428968 119538.5 -3.58854 0.022992
Year 220.5714 59.5756 3.702379 0.020792
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Figure 1. Structure and relationships between the simulation variables
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Figure 2. Simulated and historical values of 6 key variables between 2004 and 2011. The 
difference between these values was <1% in all cases
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Figure 3. Forecasted and historical values of the number of adult LT waitlist candidates from 
2004 through 2014
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Figure 4. Simulated values of 6 key variables between 2010 and 2030
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Figure 5. Projection of number of donors and number of livers used assuming that current 
trends remain in place -- (a) Donor Pool Remains Constant (b) Donor Pool Increases by 3% per 
year
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Figure 6. Projection of number of donors and number of livers used assuming changes in current 
trends -(a) Donor Pool Remains Constant (b) Donor Pool Increases by 3% per year
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Figure 7. Projection of number of donors and number of livers if used reperfusion technology 
improves (Scenarios IIIa-IIIc) compared to Scenario I, when and donors remain constant
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Figure 8. Prediction of gap between supply and demand for LTs, assuming the donor pool 
remains constant -- (a) Waitlist size remains constant after 2014 (b) Waitlist size grows as 
predicted
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